Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 11:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Acute Myocardial Infarction
Interventions
Selatogrel, Placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
81
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 72 more
Conditions
Myasthenia Gravis
Interventions
Nipocalimab, Placebo, Nipocalimab SC-LIV
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more
Conditions
Heart Failure
Interventions
Medtronic Pacemaker
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Terminated Phase 1 Interventional Results available

Direct Peritoneal Resuscitation in Gastroschisis

NCT03205553
Conditions
Gastroschisis
Interventions
SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
Procedure · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 12 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Cholangiocarcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Pancreatitis
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-opioids for Analgesia After Adenotonsillectomy in Children

NCT03618823
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen
Drug
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
Interventions
CNM-Au8, Placebo
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Post Operative Analgesia, Bariatric Surgery, Bariatric Surgery (Gastric Bypass), Bariatric Surgery Patients, Perioperative Analgesia
Interventions
Acetaminophen
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Conditions
COPD
Interventions
InnoSpire Go, Jet Nebulizer
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Clairton, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

NCT04063124
Conditions
Alzheimer Disease
Interventions
Dasatinib + Quercetin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions
UX007, Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more
Conditions
Healthy Volunteers
Interventions
TBPM-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Migraine Headache
Interventions
Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL
Other · Drug
Lead sponsor
University of Louisville
Other
Eligibility
8 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide Injection Solution 8mg/mL
Drug
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Pediatric Lumbar Puncture
Interventions
Normal Saline Intravenous Fluids
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Months to 3 Months
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Barrett's Esophagus
Interventions
trūFreeze™ Spray Cryotherapy
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
Conditions
Anterior Segment of Eye
Interventions
Lightfield Medical Vscan001 Automated Slit-lamp Camera
Device
Lead sponsor
Lightfield Medical
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Golden Valley, Minnesota